| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52131a98b9273e318f265d5c46c28cbe |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-832 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
1990-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1993-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69bdd98d77a179f6bafc4bdfb45e60d |
| publicationDate |
1993-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5185157-A |
| titleOfInvention |
Treatment of refractory Eosinophilia-Myalgia Syndrome with L-tryptophan composition |
| abstract |
A method of treating a human patient with refractory Eosinophilia Myalgia Syndrome via oral administration of an effective dosage range of from 1000 mg. to 3000 mg. of a pharmaceutical composition, in unit dosage form, comprising a minor amount of a solid or liquid carrier and a major amount of the amino acid, pharmaceutical grade L-tryptophan, or its acid addition salt, with both of the carriers and the amino acid to be selected to exclude the zinc, magnesium, and calcium containing salts as adjuvants. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11485705-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10207990-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9732035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017019175-A1 |
| priorityDate |
1990-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |